DYRK1A and leukemia: Results from in vitro drug combination testing are promising, and future directions should consider clinical evaluation in early phase trials for leukaemia, as well as for tumours with poor prognosis, such as glioblastoma or head and neck cancer, where DYRK1A has also been implicated [191,192].